2023-08-24T15:32:56-05:00 2022-12-31 951777440 GREEN HASSON & JANKS LLP 700 SOUTH FLOWER STREET SUITE 3300 LOS ANGELES CA 90017 990 2022-01-01 954418411 PROSTATE CANCER FOUNDATION PROS 3105704700 1250 FOURTH STREET 360 SANTA MONICA CA 904011353 CHARLES RYAN PRESIDENT/CEO 3105704700 2023-08-23 1 CHARLES RYAN 999009999 0 LIZBETH G NEVAREZ P01399868 3108731600 2023-08-23 2 AAL1 IAL1 2022 2023-04-26 12:10:37Z CHARLES RYAN 1250 FOURTH STREET 360 SANTA MONICA CA 904011353 72771452 0 X WWW.PCF.ORG X 1993 CA PCF IS THE LEADING PHILANTHROPIC ORGANIZATION FUNDING HIGH RISK & REWARD PROSTATE CANCER RESEARCH. 33 31 42 35 0 0 52997619 71390051 4617 4752 14514 527048 0 0 53016750 71921851 26430782 37219624 0 0 6341448 9222524 1775 0 5950014 8897782 15029920 41671787 61472068 11344963 10449783 62542873 87285836 28241088 41910195 34301785 45375641 X THE PROSTATE CANCER FOUNDATION (PCF) IS A GLOBAL BIOMEDICAL RESEARCH FUNDING FOUNDATION COMMITTED TO ENDING DEATH AND SUFFERING FROM PROSTATE CANCER. PCF ACCELERATES THE WORLD'S MOST PROMISING PROSTATE CANCER RESEARCH WITH THE GOAL OF DISCOVERING AND DEVELOPING NEW PRECISION PREVENTION, EARLIER DETECTION AND GENOMIC MEDICINES FOR PROSTATE CANCER. 0 0 25090337 25090337 THE PCF RESEARCH ENTERPRISE IS A PEER-REVIEW RESEARCH FUNDING PROGRAM THAT PROVIDES FUNDING TO 3250 SCIENTISTS CONDUCTING INNOVATIVE RESEARCH PROJECTS AT MORE THAN 250 LEADING CANCER CENTERS AND UNIVERSITIES. PRIORITY IS GIVEN TO HIGH-RISK, HIGH-RETURN PROJECTS WITH THE GREATEST POTENTIAL TO IMPROVE SURVIVAL AND THE OVERALL QUALITY OF LIFE FOR MEN WITH PROSTATE CANCER. THE CORNERSTONE OF THE PCF RESEARCH ENTERPRISE IN 2022 WAS OUR CHALLENGE AWARDS PROGRAM AND NEW TACTICAL AWARDS PROGRAM. PCF CHALLENGE AND TACTICAL AWARDS SUPPORT CROSS-DISCIPLINARY TEAMS OF INVESTIGATORS CONDUCTING PIONEERING RESEARCH TO ADDRESS CRITICAL UNMET MEDICAL NEEDS FOR PROSTATE CANCER PATIENTS. IN 2022, PCF FUNDED 19 MULTI-YEAR TEAM RESEARCH PROJECTS THAT EACH OFFER HIGH POTENTIAL FOR IMPROVED DETECTION, ENHANCED QUALITY OF LIFE AND HIGHER SURVIVAL RATES. ALL PCF-FUNDED RESEARCHERS ARE REQUIRED TO OPENLY SHARE THEIR UNPUBLISHED FINDINGS ON AN ANNUAL BASIS WITH THE ENTIRE GLOBAL RESEARCH COMMUNITY OF PCF AWARD RECIPIENTS. 6629287 6629287 PCF CREATED THE YOUNG INVESTIGATOR AWARD PROGRAM WITH ONE GOAL: TO BUILD A GIFTED COHORT OF HUMAN CAPITAL SUPPORTING THE NEXT GENERATION OF PROSTATE CANCER RESEARCHERS. AWARDS ARE MADE TO EARLY-CAREER SCIENTISTS WORKING IN A RESEARCH ENVIRONMENT CAPABLE OF SUPPORTING HIGH-IMPACT PROSTATE CANCER RESEARCH, DRAWN FROM A VARIETY OF MEDICAL RESEARCH DISCIPLINES. THE AWARD FUNDS MAY BE USED FLEXIBLY TO ADVANCE THE CAREER AND RESEARCH EFFORTS OF THE AWARDEE. MENTORSHIP IS REQUIRED FOR EVERY PCF YOUNG INVESTIGATOR. SINCE 2007, PCF HAS AWARDED MORE THAN $65 MILLION TO ADVANCE THE EARLY CAREERS OF 383 PCF YOUNG INVESTIGATORS, ENSURING A CONTINUED STREAM OF HUMAN CAPITAL INTO OUR RESEARCH COMMUNITY. MANY HAVE BECOME MAJOR RESEARCH PROGRAM LEADERS. THE PCF YOUNG INVESTIGATOR PROGRAM PLAYS AN INTEGRAL ROLE IN CHAMPIONING, MENTORING, AND IDENTIFYING STRONG LEADERSHIP POTENTIAL IN EARLY-CAREER HUMAN CAPITAL INVESTMENTS. 5500000 5500000 MORE THAN 12,000 MEN CARED FOR BY THE DEPARTMENT OF VETERANS AFFAIRS (VA) HOSPITALS ARE NEWLY DIAGNOSED WITH PROSTATE CANCER EACH YEAR, MAKING IT THE MOST FREQUENTLY DIAGNOSED CANCER AMONG VETERANS. THE PCF-VA PARTNERSHIP IS EXPANDING RESEARCH INTO PROSTATE CANCER PRECISION ONCOLOGY TREATMENT OPTIONS. THE COLLABORATION IS EXPANDING THE NUMBER OF PRECISION ONCOLOGY CLINICAL STUDIES CONDUCTED AT VETERANS HEALTHADMINISTRATION HOSPITALS, ENSURING THAT ELIGIBLE VETERANS CAN ACCESS AND PARTICIPATE IN THESE STUDIES. IN 2022, PCF'S DEDICATED NETWORK OF CENTERS OF EXCELLENCE (COE) EXECUTED THE AMBITIOUS MISSION OF IMPROVING THE CARE FOR THOUSANDS OF U.S. VETERANS WITH PROSTATE CANCER. THESE CENTERS ARE LOCATED IN PORTLAND, OR, SAN FRANCISCO, CA, PHILADELPHIA, PA, WASHINGTON, DC, DURHAM, NC, TAMPA BAY, FL, SEATTLE, WA, CHICAGO, IL, BRONX, NY, LOS ANGELES, CA, MANHATTAN, NY, ANN ARBOR, MI, ATLANTA, GA, AND BALTIMORE, MD. PCF'S VETERANS HEALTH INITIATIVE WAS FOUNDED IN 2016 AS PART OF THE CANCER MOONSHOT TO ENSURE VETERANS, WHO DESERVE THE VERY BEST FROM OUR COUNTRY, RECEIVE THE VERY BEST RESEARCH AND PRECISION ONCOLOGY CARE FOR PROSTATE CANCER AVAILABLE THROUGH THE PCF-VA NETWORK. 13337354 4752 FOR MORE THAN 3 MILLION AMERICAN MEN AND THEIR FAMILIES FIGHTING PROSTATE CANCER AND MILLIONS MORE GLOBALLY, PCF IS A PRIMARY SOURCE FOR NEW STANDARD-OF-CARE AND RESEARCH INFORMATION. PCF EDUCATES THE PUBLIC ABOUT PROSTATE CANCER RISKS, SCREENING, PREVENTION, TREATMENT OPTIONS, AND SIDE EFFECTS. WE CONNECT PATIENTS, LOVED ONES, CARE PROVIDERS AND SCIENTISTS TO CRITICAL UPDATES, THE LATEST DEVELOPMENTS, BEST PRACTICES, AND NEWS FROM THE TREATMENT PIPELINE. SINCE PCF'S INCEPTION, AND THROUGH ITS EFFORTS, PATIENTS AROUND THE WORLD ARE LIVING LONGER, SUFFERING FEWER COMPLICATIONS, AND ENJOYING BETTER QUALITY OF LIFE. PCF IS COMMITTED TO CREATING A GLOBAL PUBLIC SQUARE FOR PROSTATE CANCER, IN SERVICE TO OUR MISSION OF ENDING DEATH AND SUFFERING FROM THE DISEASE. THROUGH YEAR-ROUND AWARENESS AND EDUCATION PROGRAMS, PCF AIMS TO SPUR MEN AND WOMEN ALIKE TO TALK ABOUT THIS DISEASE, TO UNDERSTAND ITS URGENCY, AND TO HAVE INFORMATION-DRIVEN HOPE. 13337354 4752 50556978 1 1 0 1 0 0 0 0 0 0 1 0 0 0 1 1 0 1 0 0 1 1 0 0 1 0 0 1 0 1 0 0 0 0 0 0 0 0 1 0 0 0 1 0 0 0 0 1 129 0 1 42 1 0 0 0 0 0 1 1 0 0 0 0 0 0 X 33 31 1 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 1 1 0 AK AL AR AZ CA CO CT DC FL GA HI IL KS KY MA MD ME MI MN NC ND NH NJ NM NY OH OK OR PA RI SC TN UT VA WA WI WV X X HELEN HSIEH 3105704729 1250 4TH ST SUITE 360 SANTA MONICA CA 90401 CHARLES RYAN MD CEO & PRESIDENT 60.00 0.00 X X 1184923 0 63988 JONATHAN W SIMONS MD DIRECTOR 2.00 0.00 X 0 0 0 HOWARD SOULE EVP, CHIEF SCIENCE OFFICER 50.00 0.00 X 557482 0 47360 GINA CARITHERS EVP, CCO 50.00 0.00 X 376898 0 1205 HELEN HSIEH SVP, FINANCE 50.00 0.00 X 332554 0 48954 KEVIN P PICKETT EVP, CDO 50.00 0.00 X 269986 0 26960 KARI J KALSTAD EVP, COO 50.00 0.00 X 242421 0 35811 STUART HOLDEN MD DIRECTOR/MEDICAL DIRECTOR 30.00 0.00 X 225000 0 0 JULIE DIBIASE VP, ORIGINAL CONTENT 50.00 0.00 X 221571 0 12435 SHAVAUN RIGLER VP, DEVELOPMENTS 50.00 0.00 X 212009 0 13843 THE REVEREND ROSEY GRIER DIRECTOR 10.00 0.00 X 42000 0 0 MICHAEL MILKEN FOUNDER & CHAIRMAN 15.00 0.00 X X 0 0 0 LORI MILKEN DIRECTOR/VP 2.00 0.00 X X 0 0 0 RALPH FINERMAN CFO, TREASURER, SECRETARY 10.00 0.00 X 0 0 0 EMILIO BASSINI DIRECTOR 2.00 0.00 X 0 0 0 GREGORY BROWN DIRECTOR 2.00 0.00 X 0 0 0 STEVEN A BURD DIRECTOR 2.00 0.00 X 0 0 0 JOSH COHEN DIRECTOR 2.00 0.00 X 0 0 0 NEIL P DEFEO DIRECTOR 2.00 0.00 X 0 0 0 DAVID A EDERER DIRECTOR 2.00 0.00 X 0 0 0 JONATHAN P EVANS DIRECTOR 2.00 0.00 X 0 0 0 R CHRISTIAN B EVENSEN DIRECTOR 2.00 0.00 X 0 0 0 PETER T GRAUER DIRECTOR 2.00 0.00 X 0 0 0 STEIN ERIK HAGEN DIRECTOR 2.00 0.00 X 0 0 0 CLARK HOWARD DIRECTOR (LEFT 8/22) 2.00 0.00 X 0 0 0 PHILIP KANTOFF MD DIRECTOR 2.00 0.00 X 0 0 0 FREDA LEWIS-HALL MD DIRECTOR 2.00 0.00 X 0 0 0 THE HONORABLE EARLE I MACK DIRECTOR 2.00 0.00 X 0 0 0 SHMUEL MEITAR DIRECTOR 2.00 0.00 X 0 0 0 MICHAEL MULDOWNEY DIRECTOR 2.00 0.00 X 0 0 0 HENRY L NORDHOFF DIRECTOR 2.00 0.00 X 0 0 0 DAVID DREW PINSKY DIRECTOR 2.00 0.00 X 0 0 0 NEAL RODIN DIRECTOR 2.00 0.00 X 0 0 0 JASON SAFRIET DIRECTOR 2.00 0.00 X 0 0 0 RICHARD V SANDLER DIRECTOR 2.00 0.00 X 0 0 0 KEITH SHOATES DIRECTOR 2.00 0.00 X 0 0 0 THOMAS S TAD SMITH JR DIRECTOR 2.00 0.00 X 0 0 0 DAVID TAGLIGHT DIRECTOR 2.00 0.00 X 0 0 0 ROXANN TAYLOR DIRECTOR 2.00 0.00 X 0 0 0 JONATHAN USUKA DIRECTOR 2.00 0.00 X 0 0 0 PAUL VILLANTI DIRECTOR 2.00 0.00 X 0 0 0 VINCENT J VIOLA DIRECTOR (LEFT 11/22) 2.00 0.00 X 0 0 0 ANDREW C VON ESCHENBACH MD DIRECTOR (LEFT 08/2022) 2.00 0.00 X 0 0 0 KNEELAND YOUNGBLOOD DIRECTOR 2.00 0.00 X 0 0 0 JEFF ZISK DIRECTOR 2.00 0.00 X 0 0 0 3664844 0 250556 23 0 1 0 VISION MATRIX PRODUCTIONS INC 5627 KANAN ROAD STE 620 AGOURA HILLS CA 91301 EVENT PRODUCTIONS 1344466 BOULLE EVENT MANAGEMENT 1835 STALLION DR LOXAHATCHEE FL 33470 OUTREACH PROGRAM MGMT 180000 DAVE PERRON 10 GEARY AVENUE KENTFIELD CA 94904 CONSULTING 156000 G & M CONSULTING LLC 27318 SIANDRA CREEK LANE SPRING TX 77386 DATABASE MANAGEMENT 127739 4 3423360 67966691 434622 71390051 EDUCATIONAL MATERIALS 900099 4752 4752 4752 526555 526555 435155 434662 493 493 493 414939 3423360 414939 0 71921851 4752 0 527048 28018028 28018028 9201596 9201596 2498856 2194153 107803 196900 5332261 2059031 2222369 1050861 146428 54950 62382 29096 850593 344262 368224 138107 394386 184824 140797 68765 949096 478828 217680 252588 71623 20580 51043 55100 55100 452171 95977 282994 73200 571190 562417 3661 5112 739615 10473 293204 435938 514028 189932 262339 61757 602171 240905 277151 84115 498942 172158 137963 188821 9525828 6185043 152 3340633 127635 127635 490700 394260 76046 20394 119862 64180 55682 MEALS & ENTERTAINMENT 130357 45054 82040 3263 MEMBERSHIP DUES & SUBSC 93770 34676 58630 464 EDUCATION & TRAINING 53759 2926 50833 0 RESEARCH MATERIALS & SE 19945 2700 17245 0 14128 25 14103 61472068 50556978 4965076 5950014 X 2196230 1179025 0 1017205 1000 464876 38558032 35015897 19610715 39819845 170267 312142 4305228 3681360 768268 623868 6858888 3375000 4164451 59591 25869 62542873 87285836 2430391 3076989 23229447 35949555 50000 100000 2531250 1687500 0 1096151 28241088 41910195 X 17078257 31392307 17223528 13983334 34301785 45375641 62542873 87285836 X 10449783 624073 X 0 1 X 1 0 X 41744618 44877832 35831174 52997619 71390051 246841294 41744618 44877832 35831174 52997619 71390051 246841294 35438024 211403270 232385 190521 36654 14834 526555 1000949 247842243 690001 0.85300 0.92700 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 0 0 0 55522053 55522053 1000000 250000 0 0 1000000 1000000 1000000 1000000 4000000 6000000 15000 3000 18000 250000 250000 250000 250000 1000000 1500000 1072626 533757 538869 626025 626025 0 2606577 2521578 84999 623868 OPERATING LEASE LIABILITIES 1096151 1096151 X 72280137 0 72280137 -358286 -358286 71921851 61206280 497939 497939 60708341 763726 763726 61472067 PART X, LINE 2: PCF RECOGNIZES THE IMPACT OF TAX POSITIONS IN THE CONSOLIDATED FINANCIAL STATEMENTS IF THAT POSITION IS MORE LIKELY THAN NOT TO BE SUSTAINED ON AUDIT, BASED ON THE TECHNICAL MERITS OF THE POSITION. DURING THE YEAR ENDED DECEMBER 31, 2022, PCF PERFORMED AN EVALUATION OF UNCERTAIN TAX POSITIONS AND DID NOT NOTE ANY MATTERS THAT WOULD REQUIRE RECOGNITION IN THE CONSOLIDATED FINANCIAL STATEMENTS OR WHICH MIGHT HAVE AN EFFECT ON ITS TAX-EXEMPT STATUS. PART XI, LINE 4B - OTHER ADJUSTMENTS: SPECIAL EVENTS EXPENSES -414,939. FOREIGN EXCHANGE TRANSLATION 56,653. PART XII, LINE 2D - OTHER ADJUSTMENTS: SPECIAL EVENTS EXPENSES 414,939. BAD DEBT EXPENSE 83,000. PART XII, LINE 4B - OTHER ADJUSTMENTS: GRANT REFUNDS 763,726. 1 EAST ASIA AND THE PACIFIC - AUSTRALIA, BRUNEI, BURMA, CAMBODIA, 0 0 RESEARCH AWARDS CANCER RESEARCH 6116796 EUROPE (INCLUDING ICELAND & GREENLAND) - ALBANIA, ANDORRA, AUSTRIA, BELGIUM 0 0 RESEARCH AWARDS CANCER RESEARCH 2859800 NORTH AMERICA - CANADA AND MEXICO, BUT NOT THE UNITED STATES 0 0 RESEARCH AWARDS CANCER RESEARCH 225000 0 0 0 0 0 0 9201596 0 9201596 EAST ASIA AND THE PACIFIC - AUSTRALIA, BRUNEI, BURMA, CAMBODIA, CANCER RESEARCH 6116796 CHECKS 0 EUROPE (INCLUDING ICELAND & GREENLAND) - ALBANIA, ANDORRA, AUSTRIA, BELGIUM CANCER RESEARCH 2859800 CHECKS 0 NORTH AMERICA - CANADA AND MEXICO, BUT NOT THE UNITED STATES CANCER RESEARCH 225000 CHECKS 0 10 0 0 0 0 0 0 0 PART I, LINE 2: PCF MAKES AWARDS TO FOREIGN INSTITUTIONS WHICH ARE COMPARABLE TO THOSE THAT ARE TRADITIONALLY DEEMED NOT-FOR-PROFIT IN THE UNITED STATES UNIVERSITIES AND THEIR CANCER CENTERS. TO DATE, THE FOREIGN MEDICAL UNIVERSITIES AND RESEARCH INSTITUTES TO WHICH THE FOUNDATION HAS MADE AWARDS HAVE BEEN SUFFICIENTLY RENOWNED IN CANCER RESEARCH PRODUCTIVITY THAT THE FOUNDATION HAS RELIED ON THE GENERAL PUBLIC INFORMATION TO VERIFY THAT THE INSTITUTIONS ARE COMPARABLE TO UNITED STATES NOT-FOR-PROFIT ENTITIES. THE FOUNDATION APPLIES THE SAME NIH PEER REVIEW STANDARDS TO FOREIGN RESEARCH WHICH IT APPLIES TO DOMESTIC RESEARCH. PROGRESS REPORTS FOR EVALUATING RESEARCH PROPOSALS AND SUMMARIES OF FINAL RESULTS ARE REQUIRED AND REVIEWED. IN ADDITION, THE FOUNDATION CONDUCTS SITE VISITS TO EACH FOREIGN INSTITUTION TO REVIEW RESEARCH FUNDING. OTHER THAN VERIFYING THE LEGITIMACY AND CALIBER OF THE INSTITUTIONS' RESEARCH, THESE SITE VISITS ALSO HELP TO IDENTIFY POTENTIAL FUTURE AREAS OF RESEARCH COLLABORATION BETWEEN UNITED STATES AND RESEARCH TEAMS AROUND THE WORLD. PART III ACCOUNTING METHOD: HAMPTON TENNIS & DINNERS 1575000 1459235 115765 113063 2702 PALM TENNIS & DINNER 1175000 1063853 111147 106970 4177 2 1088299 900272 188027 21899 145704 17700 2724 3838299 3423360 414939 21899 365737 17700 9603 414939 0 1 MEMORIAL SLOAN KETTERING CANCER CENTER 1275 YORK AVE NEW YORK NY 10064 131924236 501(C)(3) 2770964 0 CANCER RESEARCH DANA-FARBER CANCER INSTITUTE 44 BINNEY ST BOSTON MA 02115 042263040 501(C)(3) 2330823 0 CANCER RESEARCH UNIVERSITY OF PENNSYLVANIA 3451 WALNUT STREET RM 305 PHILADELPHIA PA 19104 211352685 501(C)(3) 2301160 0 CANCER RESEARCH JOHNS HOPKINS UNIVERSITY 600 N WOLFE ST BALTIMORE MD 21287 520595110 501(C)(3) 2258050 0 CANCER RESEARCH UNIVERSITY OF CALIFORNIA SAN FRANCISCO 1600 DIVISADERO ST SAN FRANCISCO CA 94143 946036493 GOVERNMENT 2100000 0 CANCER RESEARCH UNIVERSITY OF MICHIGAN 530 S STATE ST ANN ARBOR MI 48109 386006309 GOVERNMENT 1831531 0 CANCER RESEARCH UNIVERSITY OF CALIFORNIA LOS ANGELES 405 HILGARD AVE LOS ANGELES CA 90024 956006143 GOVERNMENT 1450000 0 CANCER RESEARCH MD ANDERSON CANCER CENTER 1515 HOLCOMBE BLVD HOUSTON TX 77030 746000203 501(C)(3) 1420000 0 CANCER RESEARCH UNIVERSITY OF CHICAGO 6054 S DREXEL AVENUE CHICAGO IL 60637 362177139 501(C)(3) 1000000 0 CANCER RESEARCH ROSWELL PARK CANCER INSTITUTE ELM AND CARLTON STREETS BUFFALO NY 14263 161391608 501(C)(3) 1000000 0 CANCER RESEARCH WEILL CORNELL MEDICAL COLLEGE 575 LEXINGTON DR NEW YORK NY 10065 131623978 501(C)(3) 1000000 0 CANCER RESEARCH BOSTON DEPARTMENT OF VETERANS AFFAIRS 150 SOUTH HUNTINGTON AVENUE BOSTON MA 02130 042133157 501(C)(3) 750000 0 CANCER RESEARCH UCLA FOUNDATION 10920 WILSHIRE BLVD LOS ANGELES CA 90024 952250801 501(C)(3) 500000 0 CANCER RESEARCH THE GEORGE WASHINGTON UNIVERSITY CANCER CENTER 800 22ND STREET NW WASHINGTON DC 20052 530196584 501(C)(3) 500000 0 CANCER RESEARCH HARVARD TH CHAN SCHOOL OF PUBLIC HEALTH 330 BROOKLINE AVE BOSTON MA 02115 042103580 501(C)(3) 500000 0 CANCER RESEARCH VETERANS EDUCATION AND RESEARCH ASSOCIATION OF MICHIGAN 2215 FULLER RD ANN ARBOR MI 48105 383060217 501(C)(3) 500000 0 CANCER RESEARCH INSTITUTE FOR MEDICAL RESEARCH INC 508 FULTON DRIVE 151IMR DURHAM NC 27705 561655431 501(C)(3) 500000 0 CANCER RESEARCH BRONX VETERANS MEDICAL RESEARCH FOUNDATION 130 W KINGSBRIDGE RD NEW YORK NY 10468 133699250 501(C)(3) 500000 0 CANCER RESEARCH THE NARROWS INSTITUTE FOR BIOMEDICAL RESEARCH AND EDUCATION INC 800 POLY PL BROOKLYN NY 11209 113059740 501(C)(3) 500000 0 CANCER RESEARCH PORTLAND VA RESEARCH FOUNDATION 3710 SW US VETERANS RD PORTLAND OR 97239 943090170 501(C)(3) 500000 0 CANCER RESEARCH SEATTLE INSTITUTE FOR BIOMEDICAL AND CLINICAL REARCH INC 1325 FOURTH AVE SEATTLE WA 98108 911452438 501(C)(3) 500000 0 CANCER RESEARCH COUNT ME IN 9410 CRANLEIGH CT HOUSTON TX 77019 205164827 501(C)(3) 300000 0 CANCER RESEARCH CEDARS SINAI MEDICAL CENTER 8700 BEVERLY BOULEVARD LOS ANGELES CA 90048 951644600 501(C)(3) 275000 0 CANCER RESEARCH H LEE MOFFITT CANCER CENTER 12902 USF MAGNOLIA DRIVE TAMPA FL 33612 592451713 501(C)(3) 250000 0 CANCER RESEARCH FRED HUTCHINSON CANCER RESEARCH INSTITUTE PO BOX 19024 SEATTLE WA 98109 237156071 501(C)(3) 225000 0 CANCER RESEARCH EMORY UNIVERSITY 1390 OXFORD ROAD NE 3RD FLOOR ATLANTA GA 30322 580566256 501(C)(3) 225000 0 CANCER RESEARCH NORTHWESTERN UNIVERSITY 633 CLARK ST EVANSTON IL 60208 362167817 501(C)(3) 225000 0 CANCER RESEARCH MASSACHUSETTS GENERAL HOSPITAL 399 REVOLUTION DR STE 645 BOSTON MA 02114 042697983 501(C)(3) 225000 0 CANCER RESEARCH ST LOUIS UNIVERSITY 221 NORTH GRAND BOULEVARD ST LOUIS MO 63103 430654872 501(C)(3) 225000 0 CANCER RESEARCH MAYO CLINIC 200 FIRST STREET SW ROCHESTER MN 55905 416011702 501(C)(3) 225000 0 CANCER RESEARCH COLUMBIA UNIVERSITY MEDICAL CENTER 1130 ST NICHOLAS AVE NEW YORK NY 10032 135598093 501(C)(3) 225000 0 CANCER RESEARCH RESEARCH FOUNDATION STATE UNIVERSITY OF NEW YORK PO BOX 9 ALBANY NY 12201 141368361 501(C)(3) 225000 0 CANCER RESEARCH THE CLEVELAND CLINIC FOUNDATION 6801 BRECKSVILLE RD RK1-85 INDEPENDENCE OH 44131 340714585 501(C)(3) 225000 0 CANCER RESEARCH OREGON HEALTH & SCIENCE UNIVERSITY 2020 SW 4TH AVENUE SUITE 900 PORTLAND OR 97239 237083114 501(C)(3) 225000 0 CANCER RESEARCH UNIVERSITY OF WISCONSIN 750 HIGHLAND AVE MADISON WI 53705 396006492 501(C)(3) 225000 0 CANCER RESEARCH AMERICAN ASSOCIATION OF CANCER RESEARCH 615 CHESTNUT STREET 17TH FLOOR PHILADELPHIA PA 19106 236251648 501(C)(3) 5500 0 PUBLIC AWARENESS 36 0 PART I, LINE 2: THE FOUNDATION MONITORS THE PROGRESS OF RESEARCH THROUGH SCHEDULED SITE VISITS BY THE CHIEF SCIENCE OFFICER AND CEO AND WRITTEN PROGRESS REPORTS SUBMITTED BY THE RESEARCH INSTITUTIONS. EVERY FUNDED PCF INVESTIGATOR PARTICIPATES IN POWER POINT FORMATTED VIDEO CONFERENCES SHARING UNPUBLISHED DATA AND DATA SUBMITTED FOR PUBLICATIONS. PART I, LINE 1 THE PROSTATE CANCER FOUNDATION (PCF) HAS A TRANSPARENT AND COMPETITIVE PROCESS FOR SELECTION OF RESEARCH AWARDS. A REQUEST FOR APPLICATIONS (RFA) IS EMAILED TO POTENTIAL APPLICANTS AROUND THE WORLD AND POSTED PUBLICLY ON THE PCF WEBSITE. THE RFA LISTS THE AWARD EXPECTATIONS, DETAILED INSTRUCTIONS AND DEADLINE. COMPLETE APPLICATIONS ARE SUBMITTED ELECTRONICALLY TO PCF. EACH APPLICATION IS SENT TO 2 OR MORE SCIENTIFIC EXPERTS FOR PEER REVIEW. THE FOUNDATION EMPLOYS ALL THE PRINCIPLES AND PRACTICES OF NIH PEER REVIEWS. THE REVIEWERS ASSIGN SCORES TO THE APPLICATIONS AND ADHERE TO STRICT CONFIDENTIALITY AND CONFLICT OF INTEREST POLICIES. THE FINAL SCORES ALLOW PCF TO RANK THE APPLICATIONS FOR PRIORITY OF FUNDING. THE RANKED PROPOSALS ARE THEN PRESENTED TO AN EXPERT PANEL OF PROSTATE CANCER RESEARCHERS FOR FINAL VOTING IN A JURY FORMAT WITH SELECTION FOR FUNDING. ALL FUNDING RECOMMENDATIONS ARE SUBJECT TO THE APPROVAL OF PCF BOARD OF DIRECTORS' DISCOVERY AND TRANSLATION COMMITTEE. X X X X X 0 0 0 0 0 0 0 1 1 1 CHARLES RYAN MD CEO & PRESIDENT 634923 0 550000 0 0 0 12200 0 51788 0 1248911 0 0 0 HOWARD SOULE EVP, CHIEF SCIENCE OFFICER 477482 0 80000 0 0 0 12200 0 35160 0 604842 0 0 0 GINA CARITHERS EVP, CCO 376898 0 0 0 0 0 0 0 1205 0 378103 0 0 0 HELEN HSIEH SVP, FINANCE 312554 0 20000 0 0 0 12200 0 36754 0 381508 0 0 0 KEVIN P PICKETT EVP, CDO 269986 0 0 0 0 0 10992 0 15968 0 296946 0 0 0 KARI J KALSTAD EVP, COO 242421 0 0 0 0 0 9841 0 25970 0 278232 0 0 0 STUART HOLDEN MD DIRECTOR/MEDICAL DIRECTOR 225000 0 0 0 0 0 0 0 0 0 225000 0 0 0 JULIE DIBIASE VP, ORIGINAL CONTENT 201571 0 20000 0 0 0 4734 0 7701 0 234006 0 0 0 SHAVAUN RIGLER VP, DEVELOPMENTS 212009 0 0 0 0 0 1600 0 12243 0 225852 0 0 0 PART I, LINE 7 THE COMMITTEE AWARDED THE DISCRETIONARY BONUSES TO THE OFFICERS AND EMPLOYEES BASED ON EXCEPTIONAL INDIVIDUAL PERFORMANCE. X 19 434622 MARKET PRICE 0 0 0 PART I, COLUMN (B): THE PUBLICLY TRADED SECURITIES ARE VALUED USING THE MEAN PRICE ON THE DAY OF RECEIPT. GOODS AND SERVICES IF ANY, ARE MAILED TO THE DONORS. NONCASH CONTRIBUTIONS ARE LISTED BY NUMBER OF CONTRIBUTORS. FORM 990, PART VI, SECTION A, LINE 2 MICHAEL MILKEN (CHAIRMAN) FAMILY AND BUSINESS RELATIONSHIP; LORI MILKEN (DIRECTOR/VP) FAMILY AND BUSINESS RELATIONSHIPS; RALPH FINERMAN (TREASURER/CFO) BUSINESS RELATIONSHIP; RICHARD SANDLER (DIRECTOR) BUSINESS RELATIONSHIP. FORM 990, PART VI, SECTION B, LINE 11B FORM 990 IS REVIEWED BY THE FOUNDATION'S CEO, CFO AND EXECUTIVE VP FINANCE AND ADMINISTRATION BEFORE DISTRIBUTION TO THE AUDIT COMMITTEE FOR REVIEW AND FINAL APPROVAL. THE ENTIRE BOARD RECEIVES A COPY OF FORM 990 AND HAS AN OPPORTUNITY TO RAISE ISSUES PRIOR TO BEING FILED. FORM 990, PART VI, SECTION B, LINE 12C THE FOUNDATION'S BOARD OF DIRECTORS ADOPTED A CONFLICT OF INTEREST POLICY WHICH APPLIES TO ALL DIRECTORS AND OFFICERS CONSISTENT WITH THE MODEL SUGGESTED BY THE INTERNAL REVENUE SERVICE. THE POLICY REQUIRES THAT DIRECTORS AND OFFICERS DISCLOSE ANY TRANSACTIONS IN WHICH THEY HAVE A FINANCIAL INTEREST TO THE FOUNDATION'S GENERAL COUNSEL. THE GENERAL COUNSEL IS RESPONSIBLE FOR GATHERING INFORMATION AND PREPARING A REPORT REGARDING ANY PROPOSED TRANSACTION WHERE THERE IS A DISCLOSED FINANCIAL INTEREST AND DETERMINING WHETHER OR NOT THE TRANSACTION REASONABLY COULD BE DETERMINED TO MEET THE FOUNDATION'S STANDARDS FOR APPROVING A TRANSACTION, IN WHICH AN OFFICER OR DIRECTOR HAS A FINANCIAL INTEREST (I.E., THE BEST INTERESTS OF THE FOUNDATION FOR THE FOUNDATION'S BENEFIT AND FAIR AND REASONABLE AS TO THE FOUNDATION). IF PCF'S GENERAL COUNSEL DETERMINES THE TRANSACTION MAY MEET THE APPROVAL STANDARD, THE TRANSACTION IS REVIEWED BY AND EITHER APPROVED OR DISAPPROVED BY A COMMITTEE OF THE BOARD OF DIRECTORS OR THE ENTIRE BOARD OF DIRECTORS CONSISTENT WITH APPLICABLE STATE CORPORATE LAW REQUIREMENTS. AS PART OF THE REVIEW PROCESS, COMMITTEE OF BOARD OF DIRECTORS IS REQUIRED TO IDENTIFY AND EVALUATE POTENTIAL ALTERNATIVE TRANSACTIONS WHICH DO NOT INVOLVE A FOUNDATION OFFICER OR DIRECTOR. THE INTERESTED OFFICER OR DIRECTOR IS ALLOWED TO PRESENT INFORMATION TO THE COMMITTEE OR BOARD OF DIRECTORS BUT MUST LEAVE THE MEETING AT WHICH THE TRANSACTION IS CONSIDERED PRIOR TO THE FINAL VOTE. THE FOUNDATION'S CONFLICT OF INTEREST POLICY ALSO REQUIRES OFFICERS AND DIRECTORS TO COMPLETE ANNUAL QUESTIONNAIRES WHEREIN THEY ARE ASKED TO IDENTIFY ALL TRANSACTIONS WHERE THEY MAY HAVE AN ACTUAL OR PERCEIVED CONFLICT OF INTEREST. AS PART OF THE QUESTIONNAIRE, EACH OFFICER AND DIRECTOR IS REQUIRED TO CONFIRM THEIR UNDERSTANDING THAT THE FOUNDATION IS A TAX EXEMPT ENTITY AND MUST ENGAGE PRIMARILY IN ACTIVITIES WHICH FURTHER ITS MISSION.THE FOUNDATION'S SCIENTIFIC REVIEW PANELS DETERMINE WHICH RESEARCH PROJECTS OR TYPES OF PROJECTS WILL BE FUNDED BY THE FOUNDATION, AND ALSO HAS A CONFLICT OF INTEREST POLICY. PANELISTS ARE REQUIRED TO ABSTAIN FROM DISCUSSIONS AND VOTES REGARDING FUNDING FOR RESEARCH PROJECTS IN WHICH THEY HAVE A FINANCIAL OR PROFESSIONAL INTEREST OR INSTITUTIONAL AFFILIATION. FORM 990, PART VI, SECTION B, LINE 15 STAFF COMPENSATION, INCLUDING OFFICERS AND KEY EMPLOYEES, LISTED ON SCHEDULE J ARE REVIEWED AND APPROVED BY THE BOARD OF DIRECTORS' COMPENSATION COMMITTEE BASED ON QUALIFICATIONS AND MARKET COMPARABILITY IN SIMILAR INDUSTRIES. THE LAST COMPENSATION REVIEW OCCURRED IN DECEMBER 2022. FORM 990, PART VI, SECTION C, LINE 19 THE FOUNDATION POSTS ITS ANNUAL REPORT, AUDITED FINANCIAL STATEMENTS AND FORM 990 ON ITS WEBSITE WWW.PCF.ORG (GO TO "ABOUT PCF/WHERE YOUR MONEY GOES"). THE FOUNDATION'S GOVERNING DOCUMENTS AND CONFLICT OF INTEREST POLICY ARE ALSO POSTED ON THE WEBSITE WWW.PCF.ORG. FORM 990, PART XI, LINE 9: GRANT REFUNDS 763,726. FOREIGN EXCHANGE TRANSLATION -56,653. BAD DEBT EXPENSE -83,000. DIGITAL SCIENCE PRESS LLC 1390 IONE PRASS TRAIL RENO NV 89523 873985005 MEDICAL EDUCATION NV 5122375 2102420 PROSTATE CANCER FOUNDATION